SynKIR-310 Shows Encouraging Efficacy Against CD19-Positive Cells, Potentially Revolutionizing CAR-T Therapy
카지노 양상수 Therapeutics, a subsidiary of the HLB Group, disclosed ground-breaking preclinical research outcomes concerning blood cancer treatment at the '2024 American Society of Gene & Cell Therapy (ASGCT 2024)', convened from May 7th to 11th in Baltimore, Maryland, USA.
This presentation showcased preliminary findings of 카지노 양상수's blood cancer treatment candidate, SynKIR-310, which integrates a novel binder (DS191) targeting CD19, a key antigen in malignant B cells, into the 'KIR-CAR' next-generation CAR-T platform. By specifically binding to CD19, a distinctive marker in malignant B-cell-derived blood cancers, the therapy empowers potent immune cells such as T cells to selectively identify and eliminate cells expressing the CD19 antigen.
DS191, a recently discovered binder by the University of Pennsylvania, obtained global exclusive rights by 카지노 양상수 in August of last year. The research presentation unveiled results evaluating the efficacy of SynKIR-310 against CD19-positive cells. Initially, the cytotoxicity of SynKIR-310 against CD19-positive cells was assessed at various ratios (ranging from 1:1 to 30:1), revealing a significant escalation in cytotoxicity with increasing target cell ratios. Moreover, substantial anti-tumor effects were observed in comparison to the control group.
Furthermore, data assessing the activation of SynKIR-310 against target cells with varying CD19 expression levels exhibited a dose-dependent robust activation rate as CD19 expression levels rose. Additionally, in studies conducted on mice injected with Nalm6 tumor cells, notable inhibition of tumor cell growth was witnessed in mice treated with SynKIR-310 versus the control group, validating the efficacy of SynKIR-310 in restraining tumor growth.
During the conference, 카지노 양상수 underscored the uniqueness of SynKIR-310 compared to commercially available CAR-T therapies, hinting at its potential to significantly elevate cancer treatment efficacy in the future. Brian Kim, CEO of 카지노 양상수, remarked, "These research findings could signify a pivotal milestone in the advancement of cell therapies for blood cancer," further stating, "The KIR-CAR platform not only demonstrates efficacy in blood cancers but also extends its scalability as a next-generation CAR-T therapy by addressing the limitations observed in solid tumors."